AXSOME THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
AXSOME THERAPEUTICS, INC. (AXSM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $42.96 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $26.35, a 48.67% decline year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $51.33, a 64.78% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $31.15, a 143.93% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.77, a 26.69% increase year-over-year.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $37.40, a 2.12% decline from fiscal 2024.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $38.21, a 10.69% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $34.52, a 87.81% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $18.38, a 36.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.96 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $26.35 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $37.40 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $43.17 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $45.53 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $51.33 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $38.21 10-K · filed 2025-02-18 | |||
| 2024-09-30 | $39.57 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $32.59 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $31.15 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $34.52 10-K · filed 2024-02-23 | |||
| 2023-09-30 | $34.02 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $34.87 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $12.77 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $18.38 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $12.68 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $14.49 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $10.08 10-Q · filed 2022-05-02 | |||
| 2021-12-31 | $13.50 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $16.71 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $17.67 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $22.20 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $8.22 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $8.18 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $10.17 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $10.46 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $4.53 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $4.55 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $5.47 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $7.77 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $1.36 10-K · filed 2019-03-15 | |||
| 2017-12-31 | $3.56 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $3.72 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $3.86 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $4.73 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $3.67 10-K · filed 2017-03-07 | |||
| 2016-09-30 | $3.67 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |